Introduction: There is a pressing demand for the development of cancer-specific diagnostic
imaging tools, particularly for staging of pancreatic-, gastric- or cholangiocarcinoma, as …

Introduction: Children with diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis,
with a median overall survival of 9 months. Our aims are to determine the incidence of DIPG in …

Purpose Diffuse intrinsic pontine glioma (DIPG) is a brainstem malignancy with a median
survival of < 1 year. The International and European Society for Pediatric Oncology DIPG …

This review highlights the added value of PET imaging in Central Nervous System (CNS)
tumors, which is a tool that has rapidly evolved from a merely diagnostic setting to multimodal …

Predictive tools for guiding therapy in children with brain tumors are urgently needed. In this
first molecular drug imaging study in children, we investigated whether bevacizumab can …

Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40
years of mostly single-center, often non-randomized trials with variable patient inclusions, …

Introduction Diffuse intrinsic pontine glioma (DIPG) is a rare clinically, neuro-radiologically,
and molecularly defined malignancy of the brainstem with a median overall survival of …

Introduction This study investigates the safety, tolerability, and preliminary efficacy of combined
treatment with VEGF inhibitor bevacizumab, topoisomerase I inhibitor irinotecan, and …

Despite decades of clinical trials for diffuse intrinsic pontine glioma (DIPG), patient survival
does not exceed 10% at two years post-diagnosis. Lack of benefit from systemic …

The purpose of this phase I/II, open-label, single-arm trial is to investigate the safety,
tolerability, maximum tolerated dose and preliminary efficacy of the potential radiosensitizer …